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ABSTRACT: It is widely accepted that surface biofunctional modification may be an 
effective approach to improve biocompatibility and confer new bioactive properties 
on biomaterials. In this work, mussel adhesive protein (MAP) was applied as a 
coating on 316L stainless steel substrates (316L SS) and stents, and then either 
immobilized VEGF or CD34 antibody were added to create biofunctional films. The 
properties of the MAP coating were characterized by scanning electron microscope 
(SEM), atomic force microscope (AFM) and water contact angle test. Universal 
tensile testing showed that the MAP coating has adequate adhesion strength on a 
316L stainless steel material surface. Subsequent cytotoxicity and hemolysis rate tests 
showed that the MAP coatings have good biocompatibility. Moreover, using N-(3-
Dimethylaminopropyl)-N`-ethylcarbodiimide hydrochloride and N-
hydroxysulfosussinimide (EDC/NHS) chemistry, VEGF and CD34 antibody were 
immobilized on the MAP coatings. The amount and immobilized yield of VEGF on 
the MAP coatings were analyzed by enzyme-linked immuno-assays (ELISA). Finally, 
an endothelial cells culture showed that the VEGF biofunctional film can promote the 
viability and proliferation of endothelial cells. An in vitro CD34+ cells capturing test 
also verified the bioactive properties of the CD34 antibody coated stents. These 
results showed that the MAP coatings allowed effective biomolecule immobilization, 
providing a promising platform for vascular device modification.
Keywords: Vascular stents; Mussel adhesive protein (MAP); Covalent binding; 
Biomolecule; Biofunctional films
1. Introduction
Vascular stents are the most commonly used treatment for coronary artery 
disease, a condition which continues to be the leading cause of death in the western 
world and many other developed countries [1-3]. While coronary artery stenting is 
now relatively mature, significant scientific and technological challenges still remain, 
particularly in relation to in-stent restenosis (ISR) and late stent thrombosis (LST) [4]. 
Despite intense research in the last decade, the latest generation of coronary stents 
have only slightly reduced revascularisation rates compared to their first generation 
counterparts. Revascularisation rates are still 3-5% per annum with the latest devices 
[5], representing hundreds of thousands of patients worldwide. LST associated with 
delayed healing remains a major concern and has led to a need for prolonged 
treatment with expensive dual anti-platelet therapy. It is believed that ISR and LST 
may be tackled by accelerating the arterial healing process following stent 
deployment, and in particular reducing the time taken for a functional endothelium to 
cover the stent struts.
The vascular stents currently applied in the clinic are predominantly made of 
stainless steel, titanium, and cobalt-based alloys. Although these metal materials have 
good biomechanical performance and corrosion resistance, their biocompatibility is 
typically poor [6-8]. To improve biocompatibility and bioactivity, various surface 
modifications may be adopted to modify these materials. Current surface 
functionalization methods include plasma treatment, deposition of self-assembled 
monolayers (SAM), functionalized silanes, Langmuir-Blodgett films, layer-by-layer 
(LBL) assembly, and engineered peptide-binding surfaces [9-14]. Although these 
methods are widely established in laboratory research, they have substrate-dependent 
limitations in more widespread applications. In addition, vascular stents as a kind of 
blood-contacting artificial device need excellent hemocompatibility [15,16]. 
Hemocompatibility frequently is seen as the most critical aspect of biocompatibility, 
as adverse effects are not restricted locally but affect remote and vital organs. So, it is 
important to modify biomaterilas used as vascular stents with good hemocompatibility. 
However, the hemocompatibility of these conventional surface functionalization is 
still far from the ideal [17]. Therefore, there is a growing need to develop new coating 
technologies which can customized to different biomaterials and possessed good 
hemocompatibility. 
Mussel adhesive protein (MAP) is extracted from marine mussels (Mytilus edulis),  
their adhesive potential have been extensively studied by researchers [18, 19]. 
Mussels are promiscuous fouling organisms and have been shown to attach to 
virtually all types of inorganic and organic surfaces, including classically adhesion-
resistant materials such as poly (tetrafluoroethylene) (PTFE). Up until now, MAP has 
been studied extensively in the literature. Clues to MAP’s adhesive versatility may lie 
in the amino acid composition of proteins, which are rich in 3, 4-dihydroxy-L-
phenylalanine (DOPA) (content at 10-30 moL%) which is a catabolic amino acid that 
is produced by post-translational modification of tyrosine [20-22]. Previous studies of 
MAPs have proposed that the adhesion depends on DOPA [23] which may form 
strong covalent and noncovalent interactions with substrates [24], and the higher the 
DOPA content, the stronger the adhesion [25]. However, the adhesion mechanism of 
MAPs remains unresolved. Currently, at least 12 proteins have been characterized 
from the byssus of Mytilus species [26]. Among them, Mytilus edulis foot protein-1 
(Mefp-1), the primary cuticular protein, was the first byssal protein to be isolated 
from M. edulis, which has undergone much scrutiny. Mefp-1 has up to 15 mol% 
DOPA and a mass of 108 kDa [18].  
Due to MAP’s high-binding capacity, MAP and recombinant MAP have wide 
application in the fields of surface chemistry, biomedical science and ocean 
engineering, to name but a few [27-31]. Moreover, a few investigators have also 
studied the biocompatibility of MAPs and have reported that they elicit minimal 
immune response and cytotoxicity [32-34]. The properties of MAPs make them a 
promising candidate as a surface coating to modify stent materials. However, to the 
best of our knowledge there are no studies which consider the application of MAP to 
stent materials. Conferring bioactive properties to biomaterials via 
biomacromolecules such as growth factors or antibodies is a promising way to create 
new biofunction on implants [35]. Vascular endothelial growth factor (VEGF) is a 
potent inducer of endothelial cell (EC) proliferation, migration and tube formation, 
and is a key mediator in the process of angiogenesis [36-38]. There has been 
tremendous success in using biomaterials for immobilizing VEGF to induce 
neovascularization, as well as to support cell survival and differentiation [39-42]. 
CD34 is the main surface marker for endothelial progenitor cells EPCs [43]. Fixing 
CD34 antibody on the stent surface represented the earliest method to fabricate 
capture stents [44-46]. So far, the medical device company Orbus Neich has 
developed three Genous series products in which CD34 antibodies were used as 
capture molecules. These stents usually utilize the polymer as a coating, however the 
adhesion strength between the polymer and the stents material is not strong enough.
The objective of this study was to explore a new coating approach on stent 
materials using MAP and to subsequently immobilize biomacromolecules on this 
coating to create bioactive films. VEGF and CD34 antibody were chosen as 
representative biomolecules and immobilized onto a MAP coated surface (Figure 1). 
The properties of the MAP coating are then characterized. The amount and 
immobilized yield of VEGF bound to MAP coating were determined. Finally, to 
provide evidence for its retained biological activity after immobilization, VEGF 
functionalized substrates were evaluated in a culture of endothelial cells and the 
capture ability of CD34 antibody coated stents were tested through capturing CD34+ 
cells in vitro.
Figure 1. Surface modification with MAP coating and further biofunctionalization by 
immobilizing VEGF or CD34 antibody through EDC/NHS chemistry.
2. Materials and methods 
2.1. Materials 
MAP was obtained from Jiangyin USUN Biochemical Technology, Co. Ltd 
(Jiangyin, China), the main component of MAP is Mefp-1. 316 L stainless steel stents 
were obtained from BEIJING AMSION Co. Ltd. (Beijing, China). 316L stainless 
steel substrates (diameter = 15 mm) were purchased from Western Metal Materials Co. 
Ltd (Shanghai, China). VEGF, Phycoerythrin (PE) labeled anti-human CD34 and 
anti-human CD34 was purchased from BioLegend (San Diego, USA). Glutaraldehyde 
solution (25% in water) was purchased from Solarbio (Beijing, China). Sulfo-NHS 
(N-hydroxysulfosussinimide) was purchased from Thermo Scientific (Waltham, 
USA). EDC (N-(3-Dimethylaminopropyl)-N`-ethylcarbodiimide hydrochloride) was 
purchased from Sigma-Aldrich (Billerica, USA). The sources of the various reagents 
used for the evaluation of hemocompatibility and cytocompatibility are mentioned in 
the description of experiments below. Other reagents were local products of analytical 
grade.
2.2. Preparation of MAP coating on 316L stainless steel substrates 
MAP solution was prepared by diluting stock solution (10 mg/ml) to 2mg /ml 
with 1% (v/v) acetic acid buffer and to promote the adhesion of the MAP on the 
substrates the pH of the MAP solution was adjusted to 7.0 ~ 7.5 before use. Mirror 
polished 316L SS disks (Ø =10 mm) were directly immersed in MAP solution (This 
MAP coating was denominated as MC) or immersed after adding 25% 
Glutaraldehyde (2 μL/mL) which can enhance the crosslinking of the MAP (This 
MAP crosslinked coating was denominated as MCC) for 6 hours at room temperature. 
After that, the MAP deposited films were cleaned with distilled water under 
ultrasound (10 min×3 times), then were nitrogen-dried.
2.3. Immobilization of VEGF on MAP coated substrates
The MAP coated substrates were activated with EDC/NHS (N-ethyl-N-(3-
dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide) for 30 min at room 
temperature. 4 mg/mL EDC and 2.4 mg/mL NHS were used. Following activation, 
the samples were transferred to 0.5 mg/mL or 1 mg/ml VEGF in phosphate buffered 
saline (PBS; pH 7.6) at 25℃ and kept in the dark for 3h. Then the obtained surfaces 
were washed 3 times in PBS to remove excess reagents and non-covalently bound 
VEGF. Using EDC/NHS chemistry to covalently immobilize VEGF on MC and MCC 
were denominated as MC/EDC/VEGF and MCC/EDC/VGEF, and without EDC/NHS 
chemistry to immobilize VEGF on MC and MCC were denominated as MC/VEGF 
and MCC/VGEF. Prior to cell seeding, VEGF-functionalized substrates were stored in 
PBS at 4◦C.
2.4. Preparation of CD34 antibody coated stents
  MAP coating 316L stainless steel bare metal stents (BMS) (1.8mm×17 mm, 
diameter×length, China) were prepared as previous processing in section 2.2. The 
MAP coated stents were activated with EDC/NHS for 30min at room temperature. 4 
mg/mL EDC and 2.4 mg/mL NHS were used. Following activation, the samples were 
transferred to 200 μg/mL phycoerythrin labeled CD34 antibody (PE-anti-CD34) or 
CD34 antibody in phosphate buffered saline (PBS, pH 7.6) at 25℃ and kept in the 
dark for 3h. PE anti-human CD34 antibody functionalized films were continuously 
washed with PBS several times and then for visualization under fluorescence 
microscopy to evaluate the presence of bound antibodies. To test the stable bond of 
antibody, the PE anti-human CD34 antibody functionalized stents were continuously 
washed with PBS under mechanical shaking for 24 h, and then visualized under 
fluorescence microscopy. Prior to the cell capture test, CD34 stents were stored in 
PBS at 4◦C. 
2.5. Characterization of MAP coating properties
Morphology and surface roughness of the prepared MAP coating were visualized 
using scanning electron microscopy (SEM, Vega II-LMH, Germany) and atomic force 
microscopy (AFM, N8 NEOS, Bruker Nano-GmbH, Bremen, Germany). Roughness 
measurements are further performed on 3 images of scan size of (15×15) µm2 from 
different area of the same sample to ensure homogeneity. Surface wettability was 
examined by observing the water contact angle on the coatings (Pheonix 300, Surface 
Electro Optics, Suwon, Korea). All samples were kept flat, 10 µL of water was 
dropped on the films, and the images of the droplet on the films were captured 5 s 
after dropping. The water contact angle was measured using Image-Pro Plus (Media 
Cybernetics, Bethesda, MD).
2.6. Adhesion strength
The adhesion strength of the coating layer was measured by tensile test methods. 
Firstly, MAP solution (2mg/ml, with or without glutaraldehyde) was dropped on a 
316L stainless steel substrate and then another substrate put on the MAP coated 
substrate. After the MAP between the substrates was dry, the two stainless steel 
substrate were fixed by fixture. Tensile testing was performed using a tensile testing 
machine (TInius Dlsen H5K-S) with a 25 N load mechanical sensor at a constant 
speed of 1.0 mm/min and record the maximum peak. The adhesion strength was 
tested using both vertical and shear direction loading.
2.7. Balloon expansion and stability tests
The surface morphology of the BMS coated with MAP was examined by 
scanning electron microscopy (SEM, Vega II-LMH, Germany) before balloon 
expansion. A 1.8 mm × 17 mm BMS coated with MC and MCC was mounted onto an 
angioplasty balloon and the balloon was dilated from 1.8 mm to 3.0 mm (diameter) at 
a pressure of 8 atm. The post-expansion stents were examined by SEM.
2.8. Hemolysis rate
In order to test hemolysis rate of the samples, rabbit blood samples were 
obtained. 4 mL blood was diluted by 5 mL of 0.9% (w/v) sodium chloride solution. 
Every test sample (diameter 10 mm) was extracted in 10 mL 0.9% (w/v) sodium 
chloride solution for 30 min at 37°C. Untreated 0.9% (w/v) sodium chloride solution 
and double distilled water served as negative and positive controls (n=3 each). 
Afterwards, 0.2 mL of the diluted whole blood was added and the specimens were 
continuously incubated at 37 °C for 1h. Subsequently, the solutions were centrifuged 
for 5 min at 3000 rpm. The absorbance of supernatant was measured at 540 nm using 
a microplate reader (μQuant, Bio-tek instruments Inc., Winooski, USA) to determine 
the released hemoglobin of lysed red blood cells. The hemolysis rate is calculated as 
follows:
    R= (A–C1)/ (C2–C1) ×100%, 
R: hemolysis ratio (%), A: absorbance of the sample (optical density (OD)), C1: 
absorbance of the negative controls (OD), C2: absorbance of the positive control 
(OD).
2.9. In vitro cell cytotoxicity assay of MAP coating
Cell cytotoxicity assay was assessed with an MTT assay. 100 μL ECs were seeded 
at different samples in the 96-well plate at a density of 1×105/mL and maintained in a 
humidified 37°C 5% CO2 incubator for 24 hours. Then, 20 μL of 3-(4, 5-
dimethylthiazol-2yl)-2, 5-diphenyltetrazo-lium bromide (MTT, 5 mg/mL) was added 
into each well and incubated for 4 h at 37°C. Finally, 150 μL of dimethyl sulfoxide 
(DMSO) was added to the 96-well plate. The absorbance was measured at 570 nm 
and 630 nm using an enzyme micro-plate reader (Thermo1500, USA). All 
experiments were performed in triplicate.
2.10. Detection and quantification of immobilized VEGF 
Immobilized VEGF was indirectly quantified by subtracting the amount of free, 
non-immobilized VEGF in the solution after the reaction and the washing solutions 
from the amount of free VEGF in the initial solution [47, 48]. After 3 h of incubation, 
the supernatant of the immobilization solution was collected, and the substrates were 
washed 3 times in 0.5 mL PBS. The PBS was collected and mixed with the washing 
solutions. The quantity of VEGF in the mixing solutions was analyzed by an enzyme 
linked immuno-assay (human VEGF ELISA kit, RayBiotech, Norcross, USA) 
according to manufacturer’s instructions. Briefly, mixing solutions were added to the 
96 well plates and incubated for 2.5 h, followed by incubation with a biotinylated 
anti-hVEGF antibody. Subsequently, a horse radish peroxidase (HRP)-conjugated 
streptavidin solution was applied followed by a 3, 3’, 5, 5’-tetramethylbenzidine 
(TMB) one-step solution. The latter one was enzymatically converted to a blue 
chromophore. VEGF concentration was assessed spectrophotometrically at 450 nm 
absorbance and quantified by means of a standard calibration curve. Amounts of 
immobilized VEGF are expressed as ng per substrate. The amount of immobilized 
VEGF (immVEGF), relative to the amount of free VEGF in the solution (initial 
VEGF) was quantified as immobilization yield, where
    （1） Immobilization yield (%) =  %100
FinitialVEG
immVEGF
    （2） [imm.VEGF] = [initial VEGF] − [non-reacted VEGF].
2.11. HUVECs and KG-1a cells culture
Human Umbilical Vein ECs (HUVECs) (a generous gift from Dr. Lushan Liu, 
Nan Hua University, China) in endothelial basal media RPMI 1640 (HyClone USA, 
Logan, UT) supplemented with 10% fetal bovine serum (FCS; Cambrex Corp, 
Charles City, IA) and antibiotic/antimycotics solution (Gibco Industries Inc., Langley, 
OK) were grown to confluence in T-75 polystyrene flasks (Becton Dickinson and Co., 
Franklin Lakes, NJ). Cells were cultured in a CO2 incubator (5% CO2) at 37 °C.
KG-1a cells were purchased from ATCC (ATCC CCL-246.1TM) and cultured with 
Iscove’s Modified Dulbecco’s medium supplemented with 20% fetal bovine serum. 
The cells were incubated at 37°C in a humidified atmosphere of 5% CO2 with the 
growth medium changed every 2-3 days.
2.12. Endothelial cell adhesion and proliferation 
ECs (5×104 cells per well) were seeded on different samples. After incubating 
for 30 min at 37°C, the non-adherent cells were gently washed with phosphate-
buffered saline (PBS). The cells were then fixed with 2.5% paraformaldehyde for 30 
min and incubated with 0.1% (v/v) Triton X-100 for 10 min at 37°C. Then, the cells 
were stained with FITC-phalloidin for 40 min and the nuclei were counterstained with 
DAPI for 10 min at room temperature. Images of three random fields were obtained 
under a confocal laser scanning microscope (SP8, Leica). The number of adherent 
cells was determined using Image J software.
ECs proliferation were observed by seeding ECs on different samples at a 
density of 3×104 cells/cm2. After incubation for 1, 3 and 5 days, respectively, the cells 
were fixed with 2.5% paraformaldehyde for 1h, and then were washed with PBS three 
times for 3 min. Afterwards, samples were ethanol dehydrated (ascending series of 
ethanol) and gold sputtered (10 nm). Finally, the morphology of the adherent ECs was 
examined by SEM.   
2.13. In vitro capture of CD34+ cells
For capture tests, the CD34 antibody coated stents were incubated with 1×106/mL 
of KG-1a cells in IMDM culture media for 2 h at 37°C with a shaking rate of 150 rpm. 
Captured cells on the specimens were fixed with 4% paraformaldehyde (PFA; Sigma-
Aldrich, USA) in PBS for 20 min at room temperature. The cells were then 
permeabilized using 0.5% Triton X-100 in PBS for 3min. Subsequently, the cells 
stained with DAPI. After rinses with PBS, the stents were observed under a 
fluorescence microscope (OLYMPUS BX41, Japan), and the absorbance was 
measured at 570 nm and 630nm using Gemini XPS Fluorescence Microplate Reader 
(Molecular Devices, USA).
2.13 Statistical analysis
The data obtained in this study are reported as the mean ± standard deviation. 
Data obtained in different treatment groups were statistically analyzed using statistical 
software GraphPad Prism Version 6.0 software (GraphPad, USA). To reveal 
differences among the groups, one-way ANOVA followed by Tukey’s test was used. 
The differences were considered significant at *p < 0.05.
3. Results 
3.1. Surface morphology and hydrophilicity of the MAP coating
The surface morphology and roughness were observed with SEM and AFM after 
modification. The SEM images (Fig. 2A) and AFM images (Fig. 2B) revealed the 
difference in the surface morphology between 316L SS, MC, and MCC. 316L SS 
showed a rough surface in which a nanoscale metal texture was randomly generated, 
possibly due to mirror polished treatment. MAP coating for 6 h dramatically changed 
the surface morphology of 316L SS, and the nanoscale metal texture almost 
disappeared both in MC and MCC. The MCC was flatter than MC. The average 
roughness (Ra) of 316L SS, MC and MCC were 7.46 ± 1.6 nm, 9.93 ± 2.5 nm and 
5.93 ± 2.2 nm, respectively. The MCC surface was observed to be relatively 
homogeneous compared with 316L SS and MC, whereas MC had the highest Ra. The 
MC and MCC coated 316L SS both showed increased water contact angle (WCA) as 
compared to the control 316L SS (Fig. 2C). Compared with 316L SS (49.40 ± 2.21°), 
the water contacts angles increased to 63.40 ± 2.21°(MC) and 66.3 ± 3.54° (MCC). 
Figure 2. The characterization of MC and MCC. (A) The SEM images of 316L SS, MC and MCC. 
(B) The AFM images of 316L SS, MC and MCC. (C) The water contacts angles of 316L SS, MC 
and MCC. (D) The adhesion strength of MC and MCC on 316L SS using both shear and vertical  
direction loading. The values and error bars represent the means of at least three samples and 
standard deviations with statistical significance ( **p < 0.01 ).
3.2. Adhesion strength 
The adhesion strength of the MC and MCC coating on 316L SS were shown in 
Fig. 2D. No matter using shear or vertical direction loading, the adhesion strength of 
MCC on 316L SS was significantly higher than MC. This likely attributed to the 
glutaraldehyde which enhanced the bound between MAP and 316L stainless steel 
substrates through a cross-linking reaction. In addition, for the same coating, the 
adhesion strength of shear direction was lower than vertical direction.
3.3. Balloon expansion and stability tests
Stents undergo rigorous and complex distortion when mounted onto an 
angioplasty balloon and dilated. Here stent analysis was performed as an example to 
observe the mechanical behavior of the MAP as a coating (Fig. 3) when the stents 
were dilated to 3mm at a pressure of 8 atm. It can be clearly seen from SEM images 
that the MC and MCC coating deposited on a stent was very homogeneous, 
continuous and smooth (Fig. 3A and 3B). Figure 3A and 3B showed the SEM 
micrographs of the expanded stent. After dilation, the MC and MCC coating both 
could keep intact without delamination or destruction. This revealed that the MC and 
MCC coating were sufficiently flexible to follow the deformation of the 316L SS that 
allows balloon expansion of the stent without cracking or peeling from the struts.
Figure 3. SEM micrographs of the 316L SS stents coated with MC or MCC at pre-expansion and 
post-dilation. 
3.4. Hemolysis Rate and Cell Cytotoxicity
Typically, blood is the first body fluid which comes into contact with an implanted 
foreign material. It is therefore important to demonstrate that for a blood contacting 
material, hemolysis does not occur. A hemolysis test is therefore important when 
investigating implanted medical instruments. The absorbance of MC and MCC was 
shown in Figure 4A. The MC and MCC have the similar absorbance to negative 
control. As shown in Table 1, the hemolysis ratio of MC and MCC were well within 
1%, and far below the accepted threshold value of 5% [49]. It is preliminarily 
indicated, therefore, that the MC and MCC, as a novel material, shows a sufficient 
level of hemocompatibility. The in vitro cell cytotoxicity test showed that the relative 
growth rate (RGR) of MC and MCC both exceed 99 % (Figure 4 B). This 
demonstrated that these MAP coatings have good cytocompatibility.
Figure 4. (A) The absorbance of 316 LSS, MC and MCC. (B) The relative growth rate（RGR） 
of cells cultured on 316 LSS, MC and MCC. (C) ELISA quantification of immobilized VEGF 
on MC and MCC through EDC/NHS chemistry at different initial VEGF concentrations. (D) 
The final VEGF concentrations on MC and MCC with or without EDC/NHS at the same initial 
VEGF concentration. The values and error bars represent the means of at least three samples 
and standard deviations with statistical significance (*p < 0.05, **p < 0.01 and ***p < 0.001). 
ns, no significance. 
Table 1. Hemolysis ratio of the 316L SS and MAP film (sample size: Φ15 mm, n=3)
3.5. Quantification of immobilized VEGF
Amounts of immobilized VEGF were presented as ng per substrate (each 
substrate has a diameter of 1.5cm and surface area of 1.77cm2). As a first step, the 
effect of initial VEGF concentration on the final amount of immobilized VEGF was 
evaluated. Therefore, functionalization reactions were accomplished with 0.5 or 
1mg/mL VEGF while keeping all other concentrations constant. Reactions were 
executed on MC or MCC. An initial VEGF concentration of 1 mg mL−1 resulted in a 
significant increase in VEGF concentration on both MC and MCC coated substrates 
as compared to the lower initial concentrations of 0.5 mg mL−1 (Fig. 4 C). At the 
same initial VEGF concentration (1mg/ml), the amount of VEGF bound on MCC 
were higher than MC, but there was no significant difference between MCC and MC 
(Fig. 4 C). We also found that without EDC/NHS chemistry VEGF also can 
immobilize on MC and MCC, and the amount of VEGF on MC were significantly 
higher than MCC (Fig. 4 D).
With EDC/NHS chemistry, the immobilization yields (calculated as the amount 
of immobilized VEGF relative to the amount of initial VEGF) were (6.76 ± 0.34%, or 
4.78 ± 0.2%) on MC and (8.18 ± 0.154% or 5.54 ± 0.56%) on MCC at concentrations 
of 0.5 or 1mg/ mL VEGF, respectively (Table 2). In agreement, the immobilization 
Absorbance of the sample（A）
Samples
1 2 3
Average
Hemolysis 
Rate（%）
316L SS 0.017 0.014 0.016 0.016 -0.362
MC 0.019 0.017 0.018 0.018 -0.080
MCC 0.021 0.021 0.019 0.020 0.161
Negative control 0.019 0.018 0.019 0.019
Positive control 0.826 0.854 0.861 0.847
yields on MCC were higher than MC. Previously, the conjugation yield of VEGF on 
the collagen scaffolds via EDC/NHS chemistry was approximately 3 to 5% [35]. In 
our work, the yield exceeded the previous report. We also noticed that without 
EDC/NHS chemistry there were 2.04 ± 0.047% and 1.31 ± 0.103% immobilization 
yields on MC and MCC, respectively. 
Table 2. Experimental conditions and resulting immobilization yields. (n=5)
3.6. Adhesion and proliferation of ECs
The adhesion and spreading abilities of ECs were assessed by seeded ECs on 
different samples for 30 min. As shown in Figure 5A, more ECs adhered and spread 
on MAP coating (MC/VEGF and MCC/VEGF) and VEGF covalently immobilized 
MAP coating (MC/EDC/VEGF and MCC/EDC/VEGF) compared to bare 316 LSS. 
Almost twice as many ECs were present on the surface coated with MAP compared to 
bare 316 LSS (Figure 5C). Furthermore, the average spreading area of ECs on MAP 
coating and VEGF covalently immobilized MAP coating was significantly larger than 
that on bare 316 LSS, whereas there was no significant difference between different 
MAP coating (Fig. 5 B and D). 
Samples EDC/NHS
Initial VEGF 
concentration
(mg/mL)
Amount of 
VEGF
VEGF（ng）
Immobilization yield 
(%)
MC + 1 47.77±2.06  4.78±0.2
MC + 0.5 33.78±1.72  6.76±0.34
MCC + 1 55.38±5.58  5.54±0.56
MCC + 0.5 40.88±0.77 8.18±0.154
MC - 1 20.37±0.47 2.04±0.047
MCC - 1 13.08±1.03  1.31±0.103
Figure 5. Adhesion and spreading of ECs on various samples. Morphological observations (scale 
bar 100 μm) (A), the spreading observations (scale bar 15 μm) (B), adhesive cells number (C), 
spreading area (D) of ECs on the various substrates after cell adhesion for 30 min. The initial cell 
density was 5 × 104 cells per well. Actin filaments were stained with phalloidin-FITC (green), and 
nuclei were stained with DAPI (blue). The values and error bars represent the means of at least 
three samples and standard deviations with statistical significance (**p < 0.01 and ***p < 0.001). 
ns, no significance.
To assess the function of the MAP coating containing immobilized VEGF, ECs 
were seeded on different samples and cultured for 1, 3 and 5 days. The samples were 
fixed with 2.5% glutaraldehyde and dehydrated. Finally, the specimens were 
examined by SEM. As shown in Figure 6A, with covalently immobilized VEGF, the 
proliferation of ECs was more rapid than without covalently immobilized VEGF. In 
addition, the percentage of spreading area of ECs on MC/EDC/VEGF and 
MC/EDC/VEGF was significantly higher than others for 3 and 5 days (Fig. 6B). 
These results suggested that covalently immobilized VEGF on MC and MCC 
efficiently enhanced ECs’ adhesion, spreading and proliferation.
Figure 6. (A)SEM images of ECs cultured on different treatments for 1, 3, 5 days (scale bar 50μm). 
(B) The percentage of spreading area (the spreading areas of all cells/substrates areas) of HUVECs 
on the various substrates. The values and error bars represent the means of at least three samples 
and standard deviations with statistical significance (*p < 0.05, **p < 0.01 and ***p < 0.001). ns, 
no significance.
3.7. CD34 antibody coated stents and in Vitro capture tests
To further investigate the performance of the MAP coating on stents, we 
prepared CD34 antibody coated stents through MAP coated stents. The fluorescence 
images of MAP films and PE-labeled CD34 antibody functionalized MAP films are 
illustrated in Figure 7A. There was a little red fluorescence that can be observed on 
the MC and MCC without EDC/NHS chemistry. While, in the case of PE-CD34 
antibody immobilized on MAP coating with EDC/NHS chemistry, fluorescence 
tagging of the CD34 antibodies showed uniform distribution on the surface of the 
stents under fluorescence microscopy, indicating the antibodies have been 
successfully conjugated to the MAP film. It is also clear that the fluorescence is 
stronger and more uniform on MCC compared with MC under EDC/NHS chemistry. 
Our results indicate that with EDC/NHS chemistry the amount of immobilized CD34 
antibody on MCC was higher than on MC. The films were continuously washed with 
PBS under mechanical shaking for 24 h before measurements, with no observed 
reduction in the mean fluorescence intensity measured, showing antibodies were 
stably bound（Figure 7B）.
Figure 7. (A) Fluorescence images of BMS and PE-labeled CD34 antibody immobilized on MC or 
MCC (scale bar 1mm). (B) Fluorescence images of PE-labeled CD34 antibody immobilized on 
MC and MCC before and after wash (scale bar 1mm). 
In vitro KG-1a cells were used to verify the capture ability of the CD34 antibody 
coated stents. Under fluorescence microscope with DAPI staining, the antibody-
immobilized stents were observed to successfully capture CD34+ KG-1a cells on the 
stent surface (Fig. 8A). The MCC/EDC/CD34 antibody coated stents were found to 
have the highest capture ability. The average rate of absorbance of MCC/EDC/CD34 
antibody coated was about 130 (n=3), which is comparable with a commercial CD34 
antibody coated stent (CS) (Fig. 8B). We found that the MC and MCC coatings 
without EDC/NHS to bind CD34 antibody can also capture the CD34+ cells and the 
capturing amount on MCC is less than on the MC. At the same time, we also found 
that just the MC and MCC can capture a small amount of CD34+ cells, and the 
capturing amount on MCC is less than on the MC. 
Figure 8. (A) The in vitro CD34+ cell capturing of stents with different treatments. Cells were 
stained with DAPI (blue). Commercial CD34 antibody stents (CS), (scale bar 1mm ). (B) The 
absorbance of the different stents after capturing CD34+ cells after dyeing with DAPI. The values 
and error bars represent the means of at least three samples and standard deviations with statistical 
significance (*p < 0.05, ). ns, no significance.
4. Discussion 
In this study, we reported the development of a surface coating technology through 
MAP deposition which allows for the covalent immobilization of biomolecules 
(VEGF or CD34 antibody) onto stent materials. 
Firstly, the relevant properties of the MAP coating were characterized through a 
series of tests. The MCC has better performance than MC. The surface morphology 
and roughness were observed with SEM and AFM after MAP coating. The results 
showed that MAP coating increased the average roughness, while adding 
glutaraldehyde greatly reduced the average roughness, because glutaraldehyde 
enhanced the crosslinking degree of MAP when it was deposited on substrates [50, 
51]. Ratner et al. [52, 53] hypothesized that, the surfaces of artificial heart valves 
(AHVs) and cardiovascular stents should be smooth with roughness at the level of 
protein adsorption (<50 nm), because otherwise platelets may adhere and 
thrombogenesis may occur. Obviously, the Ra of the MC and MCC coated 316L SS is 
low enough for hemocompatibility. Moreover, hemolysis rate of MC and MCC were 
tested in vitro, the results showed that both MC and MCC have a sufficient level of 
hemocompatibility. In addition, Yun Kee Jo et al. extensively analyzed the blood 
responses of the MAP coated surface in vitro. MAPs can provide with appropriate 
surface conditions based on the rapid recruitment of active molecules derived from 
body fluid and blood cells in a relatively short time after implant insertion. The 
hemostatic potential of MAP coating can provide better healing by initiating the blood 
clotting cascade [54]. A water contact angle (WCA) test showed the MAP coating 
was more hydrophobic compared to the control 316L SS. Moreover, the MCC was 
more hydrophobic than MC; the reason was that aldehyde groups of glutaraldehyde 
react with amine groups of lysine and hydroxylysine in MAP [51]. Therefore, the 
decrease of the content of hydrophilic amine groups in MAP increased the 
hydrophobicity of MCC. Similarly, the cross-linking reaction significantly increased 
adhesion strength of MCC compared with MC. We also found that the MC and MCC 
coatings were sufficiently flexible to follow the deformation of the 316L SS that 
allows balloon expansion of the stent without cracking or peeling from the struts. As 
has been reported in the literature on several occasions, cytotoxicity has proved 
undesirable side-effect of chemical crosslinking processes [50]. However, through our 
cell cytotoxicity tests, we found that MC and MCC both have good cytocompatibility. 
Taken together, our results demonstrate that MAP can be coated on metal stent 
materials through our methods. Previous study reported that at mid to higher pH 
levels the Dopa residues in MAP may oxidized into dopaquinones to enhance protein 
cross-linking [23] and the Dopa can also interact with metal ions to form metal-
catecholate complexes [57]. So, MAP can rapidly absorb on substrates to form a 
coating. Additionally, through adding the glutaraldehyde, the MCC was found to 
possess lower roughness, higher hydrophobicity and stronger adhesion than MC. 
Meanwhile, MC and MCC were both found to exhibit good biocompatibility. 
In order to stimulate the positive reaction of endothelial cells upon injury to the 
vessel wall and stent deployment, many efforts to accelerate the surface 
endothelialization of the stent has been attempted with positive results. For instance, 
bioactive proteins and polypeptides have been applied to the surface to enhance the 
attachment, viability, proliferation and retention of cells [55]. In our work, VEGF was 
further immobilized on MAP coating by EDC/NHS chemistry to create biofunctional 
coatings. To assess the binding ability of the VEGF, ELISA was used to assess the 
amounts of captured VEGF bound on the MAP coatings ELISA is a common method 
to characterize biomolecule immobilization [56]. The results indicated that, through 
EDC/NHS chemistry, VEGF was successfully covalently bound on MC and MCC. 
Under the same conditions, the amount and the bound yield on MCC are higher than 
MC, although there were no significant differences between MCC and MC. Without 
EDC/NHS chemistry, VEGF also was immobilized on MC and MCC. The reason 
may be that the MAP contains some lysine residues [57], through electrostatic 
interaction MC and MCC can bind some VEGF. However, after cross-linking reaction 
with glutaraldehyde, on MCC some lysines was reacted, which have lower 
electrostatic interaction with VEGF. We also found that using a lower concentration 
of VEGF results in higher immobilization yields when utilized with EDC/NHS 
chemistry. The results were consistent with a previous report, although the reason for 
this finding remains unclear [41]. Although it is difficult to compare our results with 
others, mainly due to this being the first study which uses MAP as a coating to 
immobilize macromolecules, it should be noted that secondary ligation of VEGF via 
the deposited MAP layer was very effective under our experimental conditions. Our 
results clearly indicated that with EDC/NHS chemistry VEGF was successfully 
immobilized on the MC and MCC in a concentration-dependent manner and the 
imbililization ability on MCC was higher than MC.
The characterization of bioactive surfaces involving grafted biomolecules is 
important to understand their biological outcomes. To detect the bioactivity of VEGF 
which immobilized on MAP coating, HUVECs were seeded on different samples in 
vitro. Our results show that that the creation of a bifunctional coating by binding 
VEGF on a MAP coating can improves the adhesion, spreading and proliferation of 
ECs. 
Many previous studies reported that EPCs may be captured by immobilizing CD34 
antibodies on stent surfaces by covalently binding to polymer carriers [58-60]. In our 
work, to further investigate the performance of MAP coating to bind biomolecules, 
CD34 antibody also was bound on MC and MCC by the same method as VEGF 
binding. Through PE-labeled CD34 antibody, we found that using the same method, 
the antibodies have been successfully conjugated to the MAP film and the binding 
amount of CD34 antibody on MCC are also higher than MC. We also found that the 
MC and MCC can bind with a certain amount of CD34 antibody without EDC/NHS 
chemistry (albeit, capturing only a few of the CD34+ cells). The results were 
consistent with previous VEGF bond on MC and MCC. In vitro capture tests showed 
that CD34 antibody coated stents in which CD34 antibody was bound on the MCC 
can capture CD34+ cells at a level comparable with a commercial CD34 antibody 
coated stent. Interestingly, just the MC and MCC also could capture a small amount of 
CD34+ cells, with the capturing amount on MCC less than the MC. This reason was 
that MAP contains some lysine residues [57]. After coating on stent materials, the 
MAP coating shows some positive charges, and normally the cell membrane shows 
negative charge. Therefore, a few cells can have adhered on MC and MCC, through 
the electrostatic interaction. Owing to using glutaraldehyde as crossing agent on MCC, 
some amine groups reacted with glutaraldehyde [51]. So, there were less cells adhered 
on MCC than MC. 
Collectively, these results suggest that MAP could be coated on stent materials 
through simple dip-coating of objects in an aqueous solution of MAP. MC and MCC 
are sufficiently flexible to follow the deformation of vascular stents during balloon 
expansion without cracking or peeling from the struts. Moreover, MCC have higher 
coating performance than MC. It is important that MC and MCC have good blood 
compatibility and cytocompatibility. The coating can further covalently bond 
biomolecules (VEGF, CD34 antibody) using EDC/NHS chemistry and MCC have 
higher binding efficiency. Importantly, the bound VEGF and CD34 antibodies on the 
MAP coating retained their bioactivity. However, we recognize that further work is 
required to demonstrate true biocompatibility of this surface. In particular, the effect 
of this new surface on platelet adhesion, thrombogenicity and inflammation warrant 
further investigation [61].
5. Conclusions
The data in this study show that MAP can be deposited onto 316L stainless steel 
(SS) stents. We demonstrated that MAP used as a stent coating shows good resistance 
to the deformation behavior of compression and expansion of a stent. Moreover, MCC 
have more favorable coating properties than MC. The MC and MCC coatings both 
have good biocompatibility. Using EDC/NHS chemistry, we successfully 
immobilized VEGF or CD34 antibody on MC and MCC coated medical 316L 
Stainless Steel substrates and stents. The immobilization efficiency on MCC was 
higher than MC under the same conditions. In vitro, the immobilized VEGF enhanced 
HUVECs proliferation and viability and the CD34 antibody coated stents have the 
ability to capture CD34+ cells, suggesting that they maintained biological activity 
after immobilization setup. In conclusion, we have developed a new method to form 
multifunctional coatings through simple dip-coating of objects in solution of MAP. In 
addition, the combination of MAP and biomolecule coating provides a potential 
strategy for controlling cell behavior on the surfaces of vascular implant materials. 
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